UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
INSIGHTS & ANALYSIS

Industry Intelligence

Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation

Research21 July 2026· 11 min read

London AI Models Accelerate Drug Discovery Pipelines

AI-guided target identification is now mandatory in London's pharma R&D pipelines, compressing lead optimisation to 14 months and pushing Phase 1 success rates above 80%. Read on.

By James Whitfield, Manufacturing & Supply Chain Writer

Regulatory14 July 2026· 8 min read

What the New UK Clinical Trials Regulations Mean for Sponsors

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, signed into law in April 2025 and entering into force on 28 April 2026, represent the most substantial revision to the UK clinical trial regulatory framework since the original 2004 Regulations…

By Dr. Eleanor Vance, Regulatory Affairs Editor

News13 July 2026· 9 min read

JAK1 Inhibitor Selectivity and What It Means for Prescribers

The Janus kinase family comprises four intracellular tyrosine kinases JAK1, JAK2, JAK3, and TYK2 that transduce signals from a broad range of cytokine receptors to downstream transcription factors, principally the signal transducer and activator of transcription (STAT) proteins.…

By Dr. Eleanor Vance, Regulatory Affairs Editor

Research9 July 2026· 9 min read

How GLP-1 Receptor Agonists Reduce Cardiovascular Risk

GLP-1 receptor agonists reduce cardiovascular risk through overlapping receptor-mediated and metabolic mechanisms. Explore the trial evidence and biology behind the benefit.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Regulatory8 July 2026· 9 min read

How NICE Evaluates Orphan Drugs Under the HST Programme

For most licensed medicines that reach the NHS in England, the route to routine clinical use runs through the NICE single technology appraisal (STA) process: a structured assessment of clinical and cost-effectiveness that applies a cost-per-quality-adjusted-life-year (QALY)…

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials6 July 2026· 9 min read

DTP3 Signals A New Route for Relapsed Myeloma Care

DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?

By Tom Okafor, Clinical Trials Correspondent

Technology2 July 2026· 7 min read

Belantamab Mafodotin Gets First-in-World MHRA Approval in Myeloma

The MHRA has granted first-in-world approval for belantamab mafodotin combination regimens in relapsed myeloma, supported by landmark DREAMM-7 and DREAMM-8 Phase 3 trial data.

By Megan Liu, Digital Health Reporter

Pharmaceutical1 July 2026· 4 min read

The UK Medical Cannabis Supply Chain: Unlicensed Medicines and Regulation Explained

Most UK medical cannabis products are unlicensed specials. Here is how they are made, imported, regulated and dispensed under a traceable, accountable supply chain.

By James Whitfield, Manufacturing & Supply Chain Writer

Clinical Trials29 June 2026· 11 min read

UK sets pathway for in vivo CRISPR gene editing trials

The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials17 June 2026· 10 min read

Microbiome on a chip could cut drug trial failures

Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.

By Tom Okafor, Clinical Trials Correspondent

Research15 June 2026· 12 min read

Liquid biopsies could reshape NHS cancer screening in 2026

Liquid biopsies NHS pilot tests multi-cancer early detection to reshape screening pathways and achieve 75% Stage I-II cancer diagnosis by 2028.

By Megan Liu, Digital Health Reporter

Research10 June 2026· 9 min read

Amyloid therapies reach limits as multi-target strategies advance

The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated that disease-modifyin

By Dr. Eleanor Vance, Regulatory Affairs Editor

Stay ahead of the curve

Subscribe to our weekly pharmaceutical intelligence digest

Browse

Popular Categories in Pharma Journal

OncologyBiotechnologyPharmaceutical CompaniesClinical ResearchRegulatory, Quality & ComplianceMedical Devices, Diagnostics & EquipmentImmunology & Inflammation
Neuroscience & CNSInfectious Disease & VaccinesRare DiseasesAnimal & Veterinary HealthIndustry Media & AssociationsCell & Gene TherapyDermatology & Aesthetics
Genomics & Precision MedicineRespiratoryCardiovascular & MetabolicContract ManufacturingConsulting, Advisory & MedCommsHaematologyOphthalmology
Private Medical Clinics (London)Recruitment & TalentDigital Health & AIFertility & IVFLab, Reagents & Research ToolsMedical & Health InsuranceWomen's Health

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy